Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CELC NYSE:HIMS NYSE:PACS NASDAQ:PGNY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$89.00-3.8%$122.45$11.27▼$151.02$4.34B0.1966,622 shs732,218 shsHIMSHims & Hers Health$25.68-8.3%$24.50$13.74▼$70.43$5.94B2.3731.21 million shs12.78 million shsPACSPACS Group$36.92-1.5%$35.11$7.50▼$43.08$5.84BN/A928,138 shs331,748 shsPGNYProgyny$25.71+0.9%$20.42$16.10▼$28.75$2.02B1.031.55 million shs644,306 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity+3.96%-29.36%-34.74%-19.70%+671.87%HIMSHims & Hers Health+2.14%+10.54%+6.55%+78.17%-47.79%PACSPACS Group+2.74%-1.37%+14.96%+9.29%+268.95%PGNYProgyny+1.96%-0.82%+34.25%+39.16%+19.62%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCELCCelcuity$89.00-3.8%$122.45$11.27▼$151.02$4.34B0.1966,622 shs732,218 shsHIMSHims & Hers Health$25.68-8.3%$24.50$13.74▼$70.43$5.94B2.3731.21 million shs12.78 million shsPACSPACS Group$36.92-1.5%$35.11$7.50▼$43.08$5.84BN/A928,138 shs331,748 shsPGNYProgyny$25.71+0.9%$20.42$16.10▼$28.75$2.02B1.031.55 million shs644,306 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCELCCelcuity+3.96%-29.36%-34.74%-19.70%+671.87%HIMSHims & Hers Health+2.14%+10.54%+6.55%+78.17%-47.79%PACSPACS Group+2.74%-1.37%+14.96%+9.29%+268.95%PGNYProgyny+1.96%-0.82%+34.25%+39.16%+19.62%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCELCCelcuity 2.83Moderate Buy$152.0970.90% UpsideHIMSHims & Hers Health 2.12Hold$28.7011.76% UpsidePACSPACS Group 2.71Moderate Buy$48.0030.01% UpsidePGNYProgyny 2.93Moderate Buy$29.6715.40% UpsideCurrent Analyst Ratings BreakdownLatest PGNY, CELC, HIMS, and PACS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026CELCCelcuity Craig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$189.00 ➝ $171.006/3/2026CELCCelcuity GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/3/2026CELCCelcuity Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$183.00 ➝ $166.006/3/2026CELCCelcuity HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$185.00 ➝ $145.006/2/2026CELCCelcuity Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$155.006/2/2026PGNYProgyny Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$29.00 ➝ $31.005/28/2026CELCCelcuity Macquarie InfrastructureSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$160.005/28/2026CELCCelcuity CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/26/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$28.00 ➝ $25.005/22/2026HIMSHims & Hers Health UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$23.005/22/2026HIMSHims & Hers Health Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$18.00 ➝ $23.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCELCCelcuityN/AN/AN/AN/A$2.17 per shareN/AHIMSHims & Hers Health$2.37B2.51$0.78 per share32.87$2.38 per share10.79PACSPACS Group$5.43B1.08$1.62 per share22.83$6.08 per share6.07PGNYProgyny$1.29B1.56$0.76 per share33.94$5.99 per share4.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCELCCelcuity-$177.04M-$3.90N/A136.92N/AN/A-244.61%-50.22%8/13/2026 (Estimated)HIMSHims & Hers Health$128.37M-$0.09N/A52.4151.61-0.56%6.10%1.52%8/10/2026 (Estimated)PACSPACS Group$191.54M$1.5623.6715.131.114.49%26.47%4.36%8/10/2026 (Estimated)PGNYProgyny$58.52M$0.7733.4119.481.335.23%13.34%9.03%8/6/2026 (Estimated)Latest PGNY, CELC, HIMS, and PACS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026CELCCelcuity-$1.07-$0.97+$0.10-$0.97$2.94 millionN/A5/11/2026Q1 2026HIMSHims & Hers Health$0.04-$0.40-$0.44-$0.40$616.84 million$608.10 million5/11/2026Q1 2026PACSPACS Group$0.42$0.50+$0.08$0.50$1.36 billion$1.42 billion5/7/2026Q1 2026PGNYProgyny$0.2560$0.50+$0.2440$0.29$326.47 million$328.50 million3/25/2026Q4 2025CELCCelcuity-$1.06-$0.97+$0.09-$0.97$1.28 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCELCCelcuityN/AN/AN/AN/AN/AHIMSHims & Hers HealthN/AN/AN/AN/AN/APACSPACS GroupN/AN/AN/AN/AN/APGNYProgynyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCELCCelcuity6.0412.3112.31HIMSHims & Hers Health2.181.691.56PACSPACS Group0.270.990.99PGNYProgynyN/A2.132.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCELCCelcuity63.33%HIMSHims & Hers Health63.52%PACSPACS GroupN/APGNYProgyny94.93%Insider OwnershipCompanyInsider OwnershipCELCCelcuity13.33%HIMSHims & Hers Health11.76%PACSPACS Group70.10%PGNYProgyny9.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCELCCelcuity4048.77 million42.27 millionOptionableHIMSHims & Hers Health2,442231.46 million204.24 millionOptionablePACSPACS Group47,455158.27 million47.32 millionOptionablePGNYProgyny31078.33 million70.58 millionOptionablePGNY, CELC, HIMS, and PACS HeadlinesRecent News About These CompaniesProgyny (PGNY) Authorizes $200M Share Repurchase ProgramJune 4 at 3:05 PM | finance.yahoo.comConservative Guidance Weighed on Progyny (PGNY) Amid Strong Demand and Solid ExecutionJune 4 at 3:05 PM | finance.yahoo.comInsider Selling: Progyny (NASDAQ:PGNY) Insider Sells 1,530 Shares of StockJune 4 at 8:34 AM | insidertrades.comProgyny (NASDAQ:PGNY) Price Target Raised to $31.00June 2 at 2:25 PM | marketbeat.comProgyny (NASDAQ:PGNY) Director Sells $137,445.00 in StockJune 1, 2026 | americanbankingnews.comEasterly Investment Partners LLC Raises Stock Position in Progyny, Inc. $PGNYJune 1, 2026 | marketbeat.comA Progyny (PGNY) Insider Sold 5,500 Shares for $137,000May 31, 2026 | fool.comKevin Gordon Sells 5,500 Shares of Progyny (NASDAQ:PGNY) StockMay 30, 2026 | insidertrades.comJupiter Asset Management Ltd. Purchases 121,233 Shares of Progyny, Inc. $PGNYMay 30, 2026 | marketbeat.comNew Progyny Study Shows Growing Demand for Human Guidance in an Increasingly Digital Healthcare SystemMay 28, 2026 | globenewswire.comProgyny Shareholders Approve Governance Changes at 2026 MeetingMay 27, 2026 | tipranks.comProgyny Announces $200 Million Share Repurchase AuthorizationMay 26, 2026 | tipranks.comProgyny, Inc. Announces Share Repurchase ProgramMay 26, 2026 | globenewswire.comUBS Group AG Cuts Position in Progyny, Inc. $PGNYMay 25, 2026 | marketbeat.comProgyny (PGNY) Is Up 7.0% After Analyst Upgrade Backed By Six Earnings Beats And 2026 OutlookMay 25, 2026 | uk.finance.yahoo.comFideuram Intesa Sanpaolo Private Banking S.P.A. Takes Position in Progyny, Inc. $PGNYMay 24, 2026 | marketbeat.comProgyny (NASDAQ:PGNY) CFO Sells $211,012.50 in StockMay 22, 2026 | insidertrades.comProgyny Inc (PGNY) Stock Down 3.8% -- Now Undervalued? GF Score: 87/100May 22, 2026 | gurufocus.comProgyny, Inc. (PGNY) Shareholder/Analyst Call TranscriptMay 21, 2026 | seekingalpha.comProgyny and Standex International have been highlighted as Zacks Bull and Bear of the DayMay 18, 2026 | sharewise.comSBull of the Day: Progyny (PGNY)May 18, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhat the FDA's Latest Proposal Means for Lilly, Novo, and HimsBy Leo Miller | May 7, 2026Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusBy Jessica Mitacek | May 8, 2026The Silver Lining of Last Week's Hims & Hers Earnings MissBy Jessica Mitacek | May 21, 2026Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?By Jessica Mitacek | May 12, 2026Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?By Jessica Mitacek | May 28, 2026PGNY, CELC, HIMS, and PACS Company DescriptionsCelcuity NASDAQ:CELC$89.00 -3.48 (-3.76%) As of 03:01 PM Eastern This is a fair market value price provided by Massive. Learn more.Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.Hims & Hers Health NYSE:HIMS$25.68 -2.33 (-8.31%) As of 03:02 PM Eastern This is a fair market value price provided by Massive. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.PACS Group NYSE:PACS$36.92 -0.55 (-1.47%) As of 03:02 PM Eastern This is a fair market value price provided by Massive. Learn more.PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.Progyny NASDAQ:PGNY$25.71 +0.23 (+0.89%) As of 03:02 PM Eastern This is a fair market value price provided by Massive. Learn more.Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
